Galbonolide A, also known by aliases such as rustmicin and erythronolide A, 6,7,10,11,12,20-hexadehydro-6-demethyl-9-deoxo-3,5,11,12-tetradeoxy-4,17-dihydroxy-6-O-methyl-3-oxo , is a naturally occurring 14-membered macrolide antibiotic with significant biological activity. Its unique chemical structure is defined by the systematic name (3R,7Z,9S,12E,14S)-14-ethyl-5-hydroxy-5-(hydroxymethyl)-7-methoxy-3,9,13-trimethyl-11-methylidene-1-oxacyclotetradeca-7,12-diene-2,4-dione, with a molecular formula of C₂₁H₃₂O₆ and a molecular weight of 380.475.
Originally identified as an inhibitor of wheat rust fungus, Galbonolide A was later found to exhibit potent antifungal activity against clinically relevant pathogenic strains, including Candida albicans and Cryptococcus neoformans. Its biosynthesis originates from bacterial sources, specifically produced by Streptomyces galbus and related Streptomyces strains such as Streptomyces sp. SR107. The biogenesis process is guided by a unique single-module, highly reducing type I polyketide synthase (PKS) system, which enables iterative assembly of propionates with precisely programmed β-keto group modifications—a distinct biochemical strategy for polyketide synthesis.
A key breakthrough in understanding its mechanism came from research at Merck Research Laboratories, which revealed that Galbonolide A exerts its fungicidal effects by inhibiting inositol phosphoceramide (IPC) synthase. This enzyme is critical for fungal sphingolipid biosynthesis, and its inhibition leads to ceramide accumulation in growing cells, ultimately resulting in cell death. Notably, mammalian sphingolipid biosynthesis lacks a corresponding enzyme, suggesting potential selective toxicity that minimizes harm to host cells.
Galbonolide A